Clinical characteristics and prognosis of non-APAP drug-induced acute liver failure: a large multicenter cohort study
Open Access
- 19 May 2023
- journal article
- research article
- Published by Springer Nature in Hepatology International
- Vol. 18 (1) , 225-237
Abstract
Background: There is growing recognition of natural history, complications, and outcomes of patients who develop non-acetaminophen (APAP) drug-induced acute liver failure (ALF). To clarify high-risk factors and develop a nomogram model to predict transplant-free survival (TFS) in patients with non-APAP drug-induced ALF. Methods: Patients with non-APAP drug-induced ALF from 5 participating centers were retrospectively analyzed. The primary endpoint was 21-day TFS. Total sample size was 482 patients. Results: Regarding causative agents, the most common implicated drugs were herbal and dietary supplements (HDS) (57.0%). The hepatocellular type (R ≥ 5) was the main liver injury pattern (69.0%). International normalized ratio, hepatic encephalopathy grades, the use of vasopressor, N-acetylcysteine, or artificial liver support system were associated with TFS and incorporated to construct a nomogram model (drug-induced acute liver failure-5, DIALF-5). The AUROC of DIALF-5 for 7-day, 21-day, 60-day, and 90-day TFS in the internal cohort were 0.886, 0.915, 0.920, and 0.912, respectively. Moreover, the AUROC of DIALF-5 for 21-day TFS had the highest AUROC, which was significantly higher than 0.725 of MELD and 0.519 of KCC (p < 0.05), numerically higher than 0.905 of ALFSG-PI but without statistical difference (p > 0.05). These results were successfully validated in the external cohort (147 patients). Conclusions: Based on easily identifiable clinical data, the novel DIALF-5 model was developed to predict transplant-free survival in non-APAP drug-induced ALF, which was superior to KCC, MELD and had a similar prediction performance to ALFSG-PI but is more convenient, which can directly calculate TFS at multiple time points.Keywords
Funding Information
- 302 Hospital Foundation (YNKTZ2018001)
- National Natural Science Foundation of China (82070584, 81600453)
- Beijing Nova Program (Z171100001117114)
- Capital Characteristic Clinic Project by Beijing Municipal Science and Technology Commission (Z181100001718034)
This publication has 36 references indexed in Scilit:
- ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver InjuryAmerican Journal of Gastroenterology, 2014
- Causes and Outcomes of Acute Liver Failure in ChinaPLOS ONE, 2013
- Lessons from look-back in acute liver failure? A single centre experience of 3300 patientsJournal of Hepatology, 2013
- Drug-Induced Acute Liver FailureHepatology, 2010
- Intravenous N-Acetylcysteine Improves Transplant-Free Survival in Early Stage Non-Acetaminophen Acute Liver FailureGastroenterology, 2009
- Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year PeriodGastroenterology, 2005
- AASLD position paperHepatology, 2005
- A Model to Predict Survival in Patients With End–Stage Liver DiseaseHepatology, 2001
- Early indicators of prognosis in fulmitant hepatic failure: an assessment of the King's criteriaJournal of Hepatology, 1997
- Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuriesJournal of Clinical Epidemiology, 1993